FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281569406> ?p ?o ?g. }

• W4281569406 endingPage "295" @default.
• W4281569406 startingPage "285" @default.
• W4281569406 abstract "BackgroundStatins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties.MethodsPatient data from three randomised, double-blind, placebo-controlled, phase III studies evaluating enzalutamide (AFFIRM, PREVAIL and PROSPER) in patients with castration-resistant prostate cancer were included in this analysis. This post hoc, retrospective study examined the association of statin and metformin on radiographic progression-free survival (rPFS), metastasis-free survival (MFS), toxicity and overall survival (OS). After adjusting for available clinical prognostic variables, multivariate analyses were performed on pooled data from AFFIRM and PREVAIL, all three trials pooled, and each trial individually, to assess differential efficacy in these end-points associated with the baseline use of these medications.ResultsIn the multivariate analysis of the individual trials, OS and rPFS/MFS were not significantly influenced by statin or metformin use in AFFIRM or PROSPER. However, in PREVAIL, OS was significantly influenced by statin (hazard ratio [HR] 0.72; 95% confidence interval [CI] 0.59–0.89) and rPFS was significantly influenced by metformin (HR, 0.48; 95% CI 0.34–0.70). In pooled analyses, improved OS was significantly associated with statin use but not metformin use for AFFIRM+PREVAIL trials (HR 0.83; 95% CI 0.72–0.96) and AFFIRM+PREVAIL+PROSPER (HR 0.75; 95% CI 0.66–0.85).ConclusionsThe association between statin or metformin use and rPFS, MFS and OS was inconsistent across three trials. Analyses of all three trials pooled and AFFIRM+PREVAIL pooled revealed that statin but not metformin use was significantly associated with a reduced risk of death in enzalutamide-treated patients. Additional prospective, controlled studies are warranted.Clinical trial registrationAFFIRM (NCT00974311), PREVAIL (NCT01212991) and PROSPER (NCT02003924)." @default.
• W4281569406 created "2022-05-27" @default.
• W4281569406 creator A5001994148 @default.
• W4281569406 creator A5002899174 @default.
• W4281569406 creator A5004985848 @default.
• W4281569406 creator A5007779528 @default.
• W4281569406 creator A5013087961 @default.
• W4281569406 creator A5016483368 @default.
• W4281569406 creator A5020692060 @default.
• W4281569406 creator A5038489185 @default.
• W4281569406 creator A5041126882 @default.
• W4281569406 creator A5048477205 @default.
• W4281569406 creator A5072378199 @default.
• W4281569406 creator A5072850546 @default.
• W4281569406 creator A5082338484 @default.
• W4281569406 creator A5082667412 @default.
• W4281569406 creator A5085333470 @default.
• W4281569406 creator A5087411305 @default.
• W4281569406 date "2022-07-01" @default.
• W4281569406 modified "2023-09-30" @default.
• W4281569406 title "Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER" @default.
• W4281569406 cites W1518093922 @default.
• W4281569406 cites W1896360033 @default.
• W4281569406 cites W2009427808 @default.
• W4281569406 cites W2045292016 @default.
• W4281569406 cites W2049818544 @default.
• W4281569406 cites W2055249407 @default.
• W4281569406 cites W2080009224 @default.
• W4281569406 cites W2111588416 @default.
• W4281569406 cites W2114687869 @default.
• W4281569406 cites W2129819340 @default.
• W4281569406 cites W2130669171 @default.
• W4281569406 cites W2148643283 @default.
• W4281569406 cites W2159771669 @default.
• W4281569406 cites W2166918329 @default.
• W4281569406 cites W2167331614 @default.
• W4281569406 cites W2171230974 @default.
• W4281569406 cites W2489425084 @default.
• W4281569406 cites W2552740808 @default.
• W4281569406 cites W2601588864 @default.
• W4281569406 cites W2609498866 @default.
• W4281569406 cites W2746574148 @default.
• W4281569406 cites W2747254784 @default.
• W4281569406 cites W2747816079 @default.
• W4281569406 cites W2779121547 @default.
• W4281569406 cites W2792640405 @default.
• W4281569406 cites W2810806599 @default.
• W4281569406 cites W2884693661 @default.
• W4281569406 cites W2898148302 @default.
• W4281569406 cites W2905502874 @default.
• W4281569406 cites W2947498878 @default.
• W4281569406 cites W2948510422 @default.
• W4281569406 cites W2963794755 @default.
• W4281569406 cites W3031020438 @default.
• W4281569406 cites W3032046986 @default.
• W4281569406 cites W3035356494 @default.
• W4281569406 cites W3089022122 @default.
• W4281569406 cites W3175482080 @default.
• W4281569406 doi "https://doi.org/10.1016/j.ejca.2022.04.005" @default.
• W4281569406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35643841" @default.
• W4281569406 hasPublicationYear "2022" @default.
• W4281569406 type Work @default.
• W4281569406 citedByCount "7" @default.
• W4281569406 countsByYear W42815694062022 @default.
• W4281569406 countsByYear W42815694062023 @default.
• W4281569406 crossrefType "journal-article" @default.
• W4281569406 hasAuthorship W4281569406A5001994148 @default.
• W4281569406 hasAuthorship W4281569406A5002899174 @default.
• W4281569406 hasAuthorship W4281569406A5004985848 @default.
• W4281569406 hasAuthorship W4281569406A5007779528 @default.
• W4281569406 hasAuthorship W4281569406A5013087961 @default.
• W4281569406 hasAuthorship W4281569406A5016483368 @default.
• W4281569406 hasAuthorship W4281569406A5020692060 @default.
• W4281569406 hasAuthorship W4281569406A5038489185 @default.
• W4281569406 hasAuthorship W4281569406A5041126882 @default.
• W4281569406 hasAuthorship W4281569406A5048477205 @default.
• W4281569406 hasAuthorship W4281569406A5072378199 @default.
• W4281569406 hasAuthorship W4281569406A5072850546 @default.
• W4281569406 hasAuthorship W4281569406A5082338484 @default.
• W4281569406 hasAuthorship W4281569406A5082667412 @default.
• W4281569406 hasAuthorship W4281569406A5085333470 @default.
• W4281569406 hasAuthorship W4281569406A5087411305 @default.
• W4281569406 hasBestOaLocation W42815694061 @default.
• W4281569406 hasConcept C121608353 @default.
• W4281569406 hasConcept C126322002 @default.
• W4281569406 hasConcept C142724271 @default.
• W4281569406 hasConcept C143998085 @default.
• W4281569406 hasConcept C204787440 @default.
• W4281569406 hasConcept C207103383 @default.
• W4281569406 hasConcept C27081682 @default.
• W4281569406 hasConcept C2776551883 @default.
• W4281569406 hasConcept C2776839432 @default.
• W4281569406 hasConcept C2779306644 @default.
• W4281569406 hasConcept C2780192828 @default.
• W4281569406 hasConcept C2780323712 @default.
• W4281569406 hasConcept C44249647 @default.
• W4281569406 hasConcept C61367390 @default.
• W4281569406 hasConcept C67761136 @default.

• next